Intracoronary Glycoprotein IIb/IIIa Inhibitors Downstream of the Coronary Occlusion: The “Highway” to Periphery

We read with interest the study of Eitel et al. (1) about the AIDA STEMI (Abciximab i.v. Versus i.c. in ST-Elevation Myocardial Infarction) trial, regarding infarct size. The study shows an interesting result: Microvascular Obstruction (MO) and infarct size did not significantly differ between intravenous versus intracoronary administration of abciximab.

http://Content.onlinejacc.org/article.aspx?articleID=1691048

Source: Journal of the American College of Cardiology: Cardiovascular Imaging - July 22, 2013 Category: Radiology Source Type: research